Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) shares rose 0.7% during trading on Tuesday . The company traded as high as $251.72 and last traded at $251.72. Approximately 53 shares traded hands during trading, an increase of 107% from the average daily volume of 26 shares. The stock had previously closed at $250.08.
Bio-Rad Laboratories Price Performance
The stock has a 50-day moving average price of $246.75 and a 200 day moving average price of $277.14. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43. The firm has a market cap of $6.85 billion, a price-to-earnings ratio of -3.30 and a beta of 0.81.
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.54 earnings per share (EPS) for the quarter. The firm had revenue of $585.40 million for the quarter. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%.
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
